PPS Trainee Awards
2022
1st place
Jeffrey Ordner, DO, New York University, New York, NY
Evidence for Continuity of Interstitial Spaces Within and Outside the Human Lung
1st place
Krasimira Rozenova, MD, PhD, Mayo Clinic, Rochester, MN
RNA Expression Profiling of Paired Biopsy and Resection Specimens of Mesothelioma Reveals Potential Novel Treatment Strategies and Targets
2nd Place:
Christopher Febres-Aldana, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Retinoblastoma (Rb) Protein in Small Cell Lung Carcinoma: Combined Genomic and Immunohistochemical Analysis with a Description of a Rare Rb-Proficient Subset
3rd Place:
Nicolas Wyvekens, MD, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Study of Molecularly Confirmed Pancreatic Adenocarcinoma (PDAC) Metastases to the Lung Can Define Morphologic Features that Distinguish Them from Primary Pulmonary Invasive Mucinous Adenocarcinoma
Naomi Hardy, MD, University of Maryland Medical Center, Baltimore, MD
Comparison of Biphasic Mesothelioma and Epithelioid Mesothelioma with Reactive Stroma and Utility of BAP1 and MTAP Expression in Identifying a True Sarcomatoid Component University of Maryland Medical Center
Marie-Pier Montminy, MD, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Molecular Profiling Is Superior to Morphology to Determine Relatedness of Multiple Lung Squamous Cell Carcinomas
2021
1st place
Matthew Gayhart, MD, Cedars-Sinair Medical Center, Los Angeles, CA
Transcriptomic Signatures in EGFR Sensitive Non-Small Cell Lung Cancer Are Associated with Early vs Late Resistance to Tyrosine
2nd place
Timothy Helland, MD, Massachusetts General Hospital, Boston, MA
Optical Imaging for Rapid, Volumetric Assessment of Tumor Adequacy in Lung Core Needle Biopsy.
Soo-Ryum Yang, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Correlation of Histologic Features with Gene Alterations in Malignant Pleural Mesothelioma.
3rd place
Marina Baine, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY
Tuft Cell Master Regulator POU2F3 is a Novel Helpful Diagnostic Immunohistochemical Marker in Neuroendocrine-Low Small Cell Lung Carcinomas.
Ildiko Krencz, MD, PhD, Semmelweiss University, Budapest, Hungary
Assessment of RICTOR Amplification and mTORC2 Activity in Small Cell Lung Carcinoma: A Comparison of Various Methods.
Rachel Fanaroff., MD University of Maryland, Baltimore, MD
Predictors of Upgrading Diffuse Malignant Mesothelioma from Epithelioid to Biphasic from Initial Sampling to Extended Pleural Decortication.
2020
1st place:
Soo-Ryum Yang, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Multifocal Invasive Mucinous Adenocarcinomas Involving Different Lobes are Clonally Related and Represent Intrapulmonary Spread as Defined by Molecular Profiling.
2nd place:
Matthew Cecchini, MD, PhD, Mayo Clinic Rochester, MN
Histopathologic and Radiologic Features of Interstitial Lung Disease in Patients with Short Telomeres.
Heather Chen, MD University of Chicago, Chicago, IL
Germline Mutated Malignant Mesotheliomas: Are These Morphologically Different from Sporadic Malignant Mesotheliomas?
3rd place
Chen Yang, MD, Memorial Sloan Kettering Cancer Center, New York, NY
UV Genomic Signature Classifies Lung Melanomas of Unknown Primary as Metastases from Occult Cutaneous Melanomas.
Cherise Meyerson, MD, UCLA Medical Center, Los Angeles, CA
Cytokeratin 7 is Superior to Lineage-Specific Markers SATB2, CDX2, and Villin in Distinguishing Primary Pulmonary Mucinous Adenocarcinoma from Metastatic Colorectal Carcinoma.
Elisabeth Tabb, MD, Massachusetts General Hospital, Boston, MA
Correlation of Gamma-Delta T-Lymphocytes and Tumor-Associated Neutrophils with Clinicopathologic, Immune, and Molecular Features in Resected Lung Adenocarcinomas.
2019
1st place:
Lauren Mecca, MD, New York-Presbyterian/Weill Cornell Medical Center, New York, NY
Clinicopathologic Characteristics of CTNNB1-Mutated Non-Small Cell Lung Carcinoma.
2nd place:
Philippe Laflamme, MD, Centre Hospitalier Universitaire de Québec-Université Laval,Quebec City, CANADA
Comparative Evaluation of the Tumor Mutational Burden and Computated Three-Dimensional Telomere Profiling as a Predictive Tool for Response to PD-1/PD-L1 Check Point Inhibitors.
Paolo Santiago Ocampo, MD, PhD, New York University Langone, New York, NY
Towards A Grading System for Stage I Adenocarcinomas of the Lung.
3rd place:
Matthew Rosenbaum, MD, Massachusetts General Hospital, Boston, MA
The Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC).
David Suster, MD, Massachusetts General Hospital, Boston, MA
Lung Adenocarcinomas with Multifocal Nodules May Have a Low rate of Recurrence Irrespective of Morphologic or Molecular Stages.
Liam Donnelly, MD, Robert Larner College of Medicine, Burlington, VT
STK11 Splice Site Variants; The Prognostic and Therapeutic Importance of Characterizing Non-Coding Alterations in Non-Small Cell Lung Tumors.
2016
1st Place:
P Dromparis, University of Alberta, Edmonton, AB, Canada
Molecular Injury and Repair Assessment in Ex Vivo Perfused Swine Lung Transplants
2nd Place:
P Desmeules, Memorial Sloan Kettering Cancer Center, New York, NY
Metastatic Lung Carcinoid Tumors: Evidence of Proliferation Rate Progression at Metastatic Sites
2nd Place:
B Driver, Houston Methodist Hospital, Houston, TX
Discordant PD-L1 Expression in Non-Small Cell Lung Carcinoma Tissue Microarray Cores Compared to Corresponding Whole Tissue Sections
3rd Place:
L Rosen, University of Chicago, Chicago, IL
Appropriate Use of Immunohistochemistry in the Diagnosis of Lung Cancer on Biopsy: A Retrospective Comparison from Four Academic Centers
A Shih, Massachusetts General Hospital, Boston, MA
Alveolar Framework Alterations in Fibrosing Interstitial Lung Disease: A Three-Dimensional Reconstruction Study
J Heyman, Columbia University Medical Center, New York, NY
PD-L1 Expression in Non-Small Cell Lung Carcinoma (NSCLC): Feasibility of Cytology and Its Comparison with Resection and Small Biopsies
2014
1st Place:
I Lamzabi, Rush University Medical Center, Chicago, IL
Epigenetic Regulation of BAX Gene in Neuroendocrine Tumors of the Lung and Its Prognostic Implication
2nd Place:
S Karimi, University Health Network, Toronto, CA
Histological Patterns of Acute Lung Injury in Lung Transplant Patients with Restrictive Allograft Syndrome (RAS)
CP Hartley, Geisel School of Medicine, Dartmouth College, Hanover, NH
Quantification of ALK from Formalin-Fixed Paraffin-Embedded Non-Small Cell Lung Cancer Tissue by Mass Spectrometry
3rd Place:
DH Hwang, Brigham and Women's Hospital, Boston, MA
Next Generation Sequence Profiling of Large Cell Carcinoma / Solid Adenocarcinoma Defines Distinct Subgroups with Implications for Rational Therapy Selection
F Hamadeh, Cleveland Clinic, Cleveland, OH
Clinicopathologic Features of Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD) vs. Sarcoidosis
BC Willis, Emory University, Atlanta, GA
c-Met Immunohistochemistry in EGFR Mutant Adenocarcinoma: Comparison with Fluorescence In-Situ Hybridization
2008
$500 Award:
Leal Herlitz, Columbia University Medical Center, New York, NY, USA
Acquisition of Invasion in Lung Adenocarcinoma: Using Laser Capture
Microdissection and Comparative Genomic Hybridization To Analyze Segmental
Copy Number Changes of Chromosome 7
$100 Awards:
Catherine Chung, University Health Network, University of Toronto,
Toronto, Canada
p16/CDKN2A Deletion as a Diagnostic Marker To Distinguish Benign from
Malignant Mesothelial Proliferations
Jonathon Herbst, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Evidence-Based Criteria To Distinguish Metastatic Breast Cancer from Primary
Lung Neoplasms on Frozen Section
Matthias Hofer, Brigham and Women's Hospital, Boston MA, USA
The Extent of Sarcomatoid Component Is an Independent Predictor of Survival
in Malignant Mesothelioma
Ruta Gupta, Cedars Sinai Medical Center, Los Angeles, CA, USA
Lessons Learnt from Mistakes and Deferrals in Frozen Section Diagnosis of
Pulmonary Lesions: An Evidence Based Pathology Approach
2005: Hannelore Kothmaier, MS, Institute of Pathology, Graz, Austria
Gene Silencing of PCNA in Mesothelioma Cell Lines Causes Deregulation of
Other Genes
2004: Deepak Mohan, MD, University of Pittsburgh Medical Center
Molecular Analysis of Mesothelial Cell Hyperplasia Assists Diagnosis
2003: Dr. Diana Ionescu, M.D. University of Pittsburgh Medical Center
Amplification in the Thymic Epithelial Tumors
2001: Eizaburo Sasatomi,
MD, Department of Pathology University of Pittsburgh Medical Center,
Pittsburgh, PA
The Majority of Lymphnode Metastasis in Non-Small Cell Lung Cancer (NSCLC)
Arise Early in Primary Lung Tumor Development
2000: Gordana Verstovsek, M.D., of
Baylor College of Medicine, Houston, Texas
Vitamin D Receptor Expression in
Emphysema: Potential for Role in Tissue Remodeling
1998: Nader T. Okby, MD, Armed
Forces Institute of Pathology and National Cancer Institute
p27 immunohistochemical expression in non-small cell lung carcinomas (NSCLC)
1997: Valerie Holst, MD, University of Pittsburgh
p53 and Kras mutational Genotyping in Pulmonary Carcinosarcoma, Spindle
Cell Carcinoma, and Pulmonary Blastoma: Implications for Histogeneis
